Despite Onconase Trial Results Quintessence Moves Ahead
WTN News - Madison, WIJune 6, 2008
In an article posted in this column a few weeks ago, it was reported that researchers at Madison-based Quintessence Bioscience were waiting for the results of a Phase IIIb clinical trial from Alfacell Corp., a significant East Coast competitor, on an anti-cancer therapeutic compound, Onconase. QBI-139, Quintessence's lead drug candidate, is very similar to Onconase but has not yet gone through clinical testing.
A Case Report: Malignant Mesothelioma with Unexpected Contralateral Mediastinal Shift
7thSpace InteractiveMay 1, 2008
An unusual clinical feature of mesothelioma is the presentation of contralateral mediastinal shift due to pleural mesothelioma tissue, rather than a pleural effusion.
Heated Intraoperative Intraperitoneal Chemotherapy Developed by Renowned Surgeon
Mesothelioma.comApril 29, 2008
Dr. Paul Sugarbaker, renowned oncologic surgeon specializing in mesothelioma at the Washington Cancer Institute, developed a leading-edge surgical procedure to treat mesothelioma called heated intraoperative intraperitoneal chemotherapy.
Comprehensive Approach for Treating Peritoneal Mesothelioma is Described
Cancer Consultants, IDApril 9, 2008
Researchers have reported that combination resection, intraperitoneal chemotherapy, and whole abdominal radiation therapy is effective for treating malignant peritoneal mesothelioma.
Radical Decortication/Pleurectomy is the Best Surgical Approach for N2 Malignant Mesothelioma: Presented at recent STS
By Ed SusmanFebruary 6, 2008
Stage 3 pure epithelial mesothelioma patients who underwent the more extensive treatment of radical decortication/pleurectomy appear to have significantly better results than patients who had less extensive operations.
Mesothelioma Subtype Shows Lengthier Projected Longevity: IASLC
By Charles Bankhead, Staff Writer, MedPage TodaySeptember 21, 2007
Some malignant mesothelioma patients may have a prognosis that's not as grim as once widely believed, said a Nordic collaborative group.
ASCO: Recent Study Confirms Pemetrexed-Platinum Activity in Malignant Mesothelioma
By Peggy Peck, Managing Editor, MedPage TodayJune 06, 2007
Confirming results of previous studies, pemetrexed combined with either cisplatin or carboplatin demonstrated activity in previously untreated malignant pleural mesothelioma, said researchers.
Chemo Combination Improves Survival in Asbestos-Related Cancer
By Lise Millay Stevens, Contributing Writer, Health Behavior News Service February 8, 2007
People with mesothelioma — a form of cancer associated with asbestos exposure — have a higher survival rate when treated with a combination of two cancer drugs, a large multicenter study finds.
Onconase Shows Unique Promise In Treating Mesothelioma
RTT News June 27, 2006
Alfacell Corp. said that according to the research findings published in National Academy of Sciences Journal, the company's anti-cancer drug Onconase might be one of the most effective methods of treatment for mesothelioma and lung cancer caused by asbestos.
FDA approves Alimta-Cisplatin Combination for treatment of Asbestos-Related Cancer
Press Release February 2, 2004
The first and only drug regimen proven to help patients with an asbestos cancer live longer was approved today by the U.S. Food and Drug Administration.
Experimental Cancer Drug Tarceva
Reuters October 9, 2002
OSI Pharmaceuticals Inc. is more confident than ever of the potential of its experimental cancer drug Tarceva (erlotinib HCl), even after the failure of a similar drug in a major clinical study this summer, OSI Chairman and CEO Dr. Colin Goddard told investors at the UBS Warburg Global Life Sciences conference here on Wednesday.